PYC Therapeutics

PYC Therapeutics (formerly Phylogica), is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells.

Cell Penetrating Peptides (CPPs) can overcome ‘the delivery challenge’ and provide access for a wide range of potent and precise drug ‘cargoes’ to the ‘undruggable genome’ – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.